DR. AARON C. PITNEY, MD

Plain English
This study looked at how body size changes in children being treated for acute lymphoblastic leukemia (ALL) over time. Researchers followed 307 children and found that while their body mass index (BMI) increased during the first two years of chemotherapy, it slightly decreased at the end of treatment. Specifically, children aged 2-9 started with a lower BMI than older kids (ages 10-18) and stayed lower throughout their treatment. Understanding these patterns is important for developing tailored support for young cancer patients. Who this helps: This benefits patients and their doctors by providing insights into weight management during cancer treatment.

Plain English
This study tested a drug called tipifarnib in children with tough-to-treat solid tumors and a genetic condition known as neurofibromatosis type 1. Researchers found that the highest safe dose for these kids was 200 mg/m2, and the drug was well tolerated, with children experiencing side effects like nausea and rash but no long-term toxicity even after multiple treatment cycles. This matters because it shows that tipifarnib can be safely given to children, potentially providing a new treatment option for difficult cases. Who this helps: This helps children with refractory solid tumors and neurofibromatosis type 1.

Plain English
Researchers studied how obesity at the time of diagnosis affects the survival of 322 predominantly Hispanic children with acute lymphoblastic leukemia (ALL). They found that being obese did not lower overall survival rates or the chances of staying cancer-free after treatment. Specifically, the risk of decreased survival related to obesity was not significant in any age group, indicating that obesity may not be as concerning in this context as previously thought. Who this helps: This information benefits pediatric cancer patients and their doctors by providing clarity on the impact of obesity in treatment outcomes for ALL.

Plain English
This study focused on 155 Hispanic children with acute lymphoblastic leukemia (ALL) to find out how many experienced high blood sugar (hyperglycemia) during the start of their chemotherapy. It found that 11% of these children developed hyperglycemia, with older age and higher body weight increasing the risk. This research highlights the importance of monitoring blood sugar in these patients, especially since obesity is common in this group. Who this helps: This helps doctors and healthcare providers better manage and support Hispanic children undergoing chemotherapy for leukemia.

Plain English
This study looked at how the body size of Hispanic children with a type of leukemia called acute lymphoblastic leukemia (ALL) changed during their treatment. Researchers followed 141 children and found that their body mass index (BMI) increased steadily during the first year of chemotherapy and remained higher throughout treatment, especially for those who were normal weight at diagnosis. This is important because it shows that these patients are at risk for gaining weight due to their treatment, which can affect their long-term health. Who this helps: This information is useful for doctors treating young patients with leukemia.